US Stock MarketDetailed Quotes
PROK ProKidney
- 1.860
- -0.180-8.82%
Close Sep 27 16:00 ET
- 1.940
- +0.080+4.30%
Post 18:50 ET
234.46MMarket Cap-3100P/E (TTM)
2.030High1.800Low905.43KVolume2.000Open2.040Pre Close1.74MTurnover1.27%Turnover RatioLossP/E (Static)126.05MShares4.85052wk High-0.24P/B132.94MFloat Cap1.12052wk Low--Dividend TTM71.47MShs Float14.190Historical High--Div YieldTTM11.28%Amplitude1.120Historical Low1.918Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
ProKidney Stock Forum
ProKidney Announces Strategic Updates to Its Phase 3 Program to Accelerate Rilparencel’s Registrational Path to Potential Approval in the U.S. Believes Phase 3 Regen-016 (Proact 2) Trial Is Not Required for Initial U.S. Registration
ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
2 mins ago
ProKidney Corp: Safety Profile Consistent With Prior Studies and Comparable to Kidney Biopsy
ProKidney Corp: Interim Results of Regen-007 Phase 2 Trial Show Stabilization of Kidney Function for 18 Months
ProKidney Corp: Resumed Manufacturing and Both Proact 1 and Proact 2 Phase 3 Trials
NEWS
ProKidney to Host Virtual KOL Event to Discuss Current Treatment Landscape of Chronic Kidney Disease Caused by Diabetes and Data from Phase 2 RMCL-002 Clinical Trial on May 28, 2024
ProKidney -- a volatile biotech that's developing kidney-disease treatments – gained 33.8% to close at $4.12 even though the company had no news or other no obvious catalysts for the rally.
The stock has had a volatile history ever since going public in 2...
No comment yet